Institute of Endocrinology and Nutrition, Medicine School and Unit of Investigation, Hospital Rio Hortega, University of Valladolid, 47130 Valladolid, Spain.
Metabolism. 2010 Apr;59(4):608-12. doi: 10.1016/j.metabol.2009.09.004. Epub 2009 Nov 14.
Some studies have pointed to a role of uncoupling protein 3 (UCP3) in the regulation of whole-body energy homoeostasis and regulation of fat distribution. The aim of our study was to investigate the influence of -55CT polymorphism of UCP3 gene on fat mass and insulin resistance in morbidly obese patients. A population of 47 obese subjects (body mass index [BMI] >40 kg/m(2)) was selected randomly in a prospective way. A nutritional evaluation was performed. Dietary intake and exercise were recorded. The mean age was 48.2 +/- 15.4 years; and the BMI was 44.7 +/- 4.7 kg/m(2), with 10 men (21.3%) and 37 women (78.7%). Thirty-two (68.1%) had the genotype -55CC (wild-type group), and 15 patients (31.9%) had -55CT (mutant-type group). In the mutant-type group, insulin (20.6+/-10.8 vs 31.2 +/- 17.4 mIU/L, P < .05), homeostasis model assessment (5.3 +/- 2.7 vs 8.7 6.6, P < .05), weight (114.1 +/- 17.3 vs 122.8+/-19.1 kg, P < .05), BMI (44.1 +/- 4.6 vs 45.7 +/- 6.3 kg/m(2), P < .05), fat mass (56.3 +/- 11.4 vs 61.4 +/- 15.1 kg, P < .05), and waist circumference (124.8 +/- 12.5 vs 128.3 +/- 9.1 cm, P < .05) were higher than those in the wild-type group. Adiponectin levels were higher in wild-type group than mutant-type group (70.3 +/- 26.1 vs 30.5 +/- 32.5 ng/mL, P < .05). In conclusion, mutant-type group of -55CC UCP3 gene patients had higher weight, fat mass, and insulin resistance than wild-type group.
一些研究指出，解偶联蛋白 3（UCP3）在调节全身能量稳态和脂肪分布方面发挥作用。我们的研究目的是探讨 UCP3 基因-55CT 多态性对病态肥胖患者脂肪量和胰岛素抵抗的影响。我们以前瞻性的方式随机选择了 47 名肥胖患者（体重指数[BMI]＞40kg/m2）。进行营养评估，记录饮食摄入和运动情况。平均年龄为 48.2±15.4 岁；BMI 为 44.7±4.7kg/m2，其中男性 10 名（21.3%），女性 37 名（78.7%）。32 名（68.1%）患者为-55CC 基因型（野生型组），15 名患者（31.9%）为-55CT 基因型（突变型组）。在突变型组中，胰岛素（20.6±10.8 vs 31.2±17.4mIU/L，P＜0.05）、稳态模型评估（5.3±2.7 vs 8.7±6.6，P＜0.05）、体重（114.1±17.3 vs 122.8±19.1kg，P＜0.05）、BMI（44.1±4.6 vs 45.7±6.3kg/m2，P＜0.05）、脂肪量（56.3±11.4 vs 61.4±15.1kg，P＜0.05）和腰围（124.8±12.5 vs 128.3±9.1cm，P＜0.05）均高于野生型组。野生型组的脂联素水平高于突变型组（70.3±26.1 vs 30.5±32.5ng/mL，P＜0.05）。综上所述，-55CC UCP3 基因突变型组患者的体重、脂肪量和胰岛素抵抗均高于野生型组。
